A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours - Ang, Yvonne L. E.; Ho, Gwo Fuang; Soo, Ross A.; Sundar, Raghav; Tan, Sing Huang; Yong, Wei Peng; Ow, Samuel G. W.; Lim, Joline S. J.; Chong, Wan Qin; Soe, Phyu Pyar; Tai, Bee Choo; Wang, Lingzhi; et al. (BMC cancer, 2020)
Keywords: Adult; Advanced solid tumours; Aged; Anti-angiogenic; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer Research; Cancer therapies; Case-Control Studies; Chemotherapy; Cyclophosphamide; Disease; Docetaxel; Docetaxel - administration & dosage; Dosage and administration; Doxorubicin; Drug dosages; Drug therapy; Enrollments; Female; Follow-Up Studies; Granulocyte colony-stimulating factor; Health Promotion and Disease Prevention; Humans; Inhibitor drugs; Lung cancer; Male; Medical and radiation oncology; Medicine/Public Health; Metastases; Middle Aged; Neoplasms - drug therapy; Neoplasms - pathology; Neutropenia; Oncology; Patients; Perfusion; Prognosis; Research Article; Short-course sunitinib; Solid tumors; Sunitinib - administration & dosage; Surgical Oncology; Survival analysis; Survival Rate; Targeted cancer therapy; Testing; Toxicity; Tumors; Tumour vasculature; Singapore; Malaysia; Advanced solid tumours; Anti-angiogenic; Docetaxel; Tumour vasculature; Short-course sunitinib